Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections

I. M. Hoepelman; W. H. Havinga; R. A. Benne; M. Zwinkels; M. A.M. de Wit; H. A.P.M. de Hond; T. A. Boon; M. R. Visser; F. W.A. van Asbeck; J. Verhoef

doi:10.1007/BF01964430

Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections

I. M. Hoepelman^*, W. H. Havinga, R. A. Benne, M. Zwinkels, M. A.M. de Wit, H. A.P.M. de Hond, T. A. Boon, M. R. Visser, F. W.A. van Asbeck, J. Verhoef

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

Abstract

Seventy patients with complicated urinary tract infections were treated with either lomefloxacin (400 mg once daily) or norfloxacin (400 mg twice daily) for 10 to 14 days. A total of 19 (86 %) of 22 patients treated with lomefloxacin and 20 (74 %) of 27 patients treated with norfloxacin were cured, as defined by a negative culture five to nine days after completion of therapy (p=0.09). After four to six weeks, the figures were 56 % for lomefloxacin and 48 % for norfloxacin. Adverse effects in the lomefloxacin group were observed on 20 occasions in 12 patients (one stopped treatment) compared to nine occasions in five patients treated with norfloxacin (difference not significant).

Original language	English
Pages (from-to)	343-347
Number of pages	5
Journal	European Journal of Clinical Microbiology & Infectious Diseases
Volume	12
Issue number	5
DOIs	https://doi.org/10.1007/BF01964430
Publication status	Published - 1 May 1993

Access to Document

10.1007/BF01964430

Cite this

Hoepelman, I. M., Havinga, W. H., Benne, R. A., Zwinkels, M., de Wit, M. A. M., de Hond, H. A. P. M., Boon, T. A., Visser, M. R., van Asbeck, F. W. A., & Verhoef, J. (1993). Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections. European Journal of Clinical Microbiology & Infectious Diseases, 12(5), 343-347. https://doi.org/10.1007/BF01964430

@article{888ab643d9a74b7ea2dd1078a9ce75a6,

title = "Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections",

abstract = "Seventy patients with complicated urinary tract infections were treated with either lomefloxacin (400 mg once daily) or norfloxacin (400 mg twice daily) for 10 to 14 days. A total of 19 (86 %) of 22 patients treated with lomefloxacin and 20 (74 %) of 27 patients treated with norfloxacin were cured, as defined by a negative culture five to nine days after completion of therapy (p=0.09). After four to six weeks, the figures were 56 % for lomefloxacin and 48 % for norfloxacin. Adverse effects in the lomefloxacin group were observed on 20 occasions in 12 patients (one stopped treatment) compared to nine occasions in five patients treated with norfloxacin (difference not significant).",

author = "Hoepelman, {I. M.} and Havinga, {W. H.} and Benne, {R. A.} and M. Zwinkels and {de Wit}, {M. A.M.} and {de Hond}, {H. A.P.M.} and Boon, {T. A.} and Visser, {M. R.} and {van Asbeck}, {F. W.A.} and J. Verhoef",

year = "1993",

month = may,

day = "1",

doi = "10.1007/BF01964430",

language = "English",

volume = "12",

pages = "343--347",

journal = "European Journal of Clinical Microbiology & Infectious Diseases",

issn = "0934-9723",

publisher = "Springer-Verlag",

number = "5",

}

Hoepelman, IM, Havinga, WH, Benne, RA, Zwinkels, M, de Wit, MAM, de Hond, HAPM, Boon, TA, Visser, MR, van Asbeck, FWA & Verhoef, J 1993, 'Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections', European Journal of Clinical Microbiology & Infectious Diseases, vol. 12, no. 5, pp. 343-347. https://doi.org/10.1007/BF01964430

TY - JOUR

T1 - Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections

AU - Hoepelman, I. M.

AU - Havinga, W. H.

AU - Benne, R. A.

AU - Zwinkels, M.

AU - de Wit, M. A.M.

AU - de Hond, H. A.P.M.

AU - Boon, T. A.

AU - Visser, M. R.

AU - van Asbeck, F. W.A.

AU - Verhoef, J.

PY - 1993/5/1

Y1 - 1993/5/1

N2 - Seventy patients with complicated urinary tract infections were treated with either lomefloxacin (400 mg once daily) or norfloxacin (400 mg twice daily) for 10 to 14 days. A total of 19 (86 %) of 22 patients treated with lomefloxacin and 20 (74 %) of 27 patients treated with norfloxacin were cured, as defined by a negative culture five to nine days after completion of therapy (p=0.09). After four to six weeks, the figures were 56 % for lomefloxacin and 48 % for norfloxacin. Adverse effects in the lomefloxacin group were observed on 20 occasions in 12 patients (one stopped treatment) compared to nine occasions in five patients treated with norfloxacin (difference not significant).

AB - Seventy patients with complicated urinary tract infections were treated with either lomefloxacin (400 mg once daily) or norfloxacin (400 mg twice daily) for 10 to 14 days. A total of 19 (86 %) of 22 patients treated with lomefloxacin and 20 (74 %) of 27 patients treated with norfloxacin were cured, as defined by a negative culture five to nine days after completion of therapy (p=0.09). After four to six weeks, the figures were 56 % for lomefloxacin and 48 % for norfloxacin. Adverse effects in the lomefloxacin group were observed on 20 occasions in 12 patients (one stopped treatment) compared to nine occasions in five patients treated with norfloxacin (difference not significant).

UR - http://www.scopus.com/inward/record.url?scp=0027230266&partnerID=8YFLogxK

U2 - 10.1007/BF01964430

DO - 10.1007/BF01964430

M3 - Article

C2 - 8394815

AN - SCOPUS:0027230266

SN - 0934-9723

VL - 12

SP - 343

EP - 347

JO - European Journal of Clinical Microbiology & Infectious Diseases

JF - European Journal of Clinical Microbiology & Infectious Diseases

IS - 5

ER -

Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections

Abstract

Access to Document

Other files and links

Fingerprint

Cite this